Figure 3. Risk of Lymphoma With Topical Calcineurin Inhibitor (TCI) Treatment in Cohort Studies.

Results are stratified by B-cell lymphoma (BCL) and T-cell lymphoma (TCL) (A) and participant age (B). Relative risks (RRs) were calculated using random-effects inverse variance method. Marker size indicates weight; diamond size indicates heterogeneity. PIM indicates pimecrolimus; TAC, tacrolimus; TCS, topical corticosteroid.

^aOther lymphoid and histiocytic tissue.

^bLymphosarcoma and reticulosarcoma.